Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly versus every-3-weeks docetaxel in chemotherapy-resistant metastatic breast cancer
NL-OMON21712Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jul 2000
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel in breast cancer (2 arms), sponsored by Sanofi. Primary endpoints: Progression-free survival and Time to treatment failure. Started Jul 2000; status: active, not recruiting.
02
Drugs
docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON21712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21712.